Advancements in Disease Modeling and Drug Discovery Using iPSC-Derived Hepatocyte-like Cells

Area of Science:

• Hepatology and Regenerative Medicine
• Stem Cell Biology
• Genomics and Bioinformatics

Background:

• The liver, a metabolic hub, is vital but susceptible to diseases, causing significant mortality and economic burden.
• Traditional models like primary hepatocytes and murine models have limitations hindering progress in liver disease research.
• Induced pluripotent stem cells (iPSCs) present a promising alternative for studying liver diseases.

Purpose of the Study:

• To review recent advancements in induced pluripotent stem cell (iPSC)-based models for liver disease research.
• To highlight improvements in constructing iPSC models and their application in high-throughput screening.
• To discuss the utility of iPSC models in genetic studies and the discovery of novel therapeutics for liver conditions.

Main Methods:

• Review of current literature on iPSC-based liver disease models.
• Analysis of advancements in iPSC differentiation and genetic manipulation (e.g., CRISPR/Cas9).
• Evaluation of high-throughput screening applications using iPSC systems for drug discovery and genetic studies.

Main Results:

• iPSC-based systems offer preserved differentiation and physiological functions relevant to liver disease.
• These models are amenable to genetic manipulation, enabling detailed mechanistic studies.
• iPSC platforms support high-throughput screening for identifying potential therapeutic targets and drugs.

Conclusions:

• iPSC-based models represent a significant advancement over traditional systems for liver disease research.
• Ongoing improvements are addressing existing limitations, making iPSC models more robust and versatile.
• These models are crucial for advancing our understanding of liver diseases and accelerating the development of new treatments.